Evotec SE (EVO)
| Market Cap | 1.09B -6.9% |
| Revenue (ttm) | 925.65M -1.1% |
| Net Income | -121.54M |
| EPS | -0.68 |
| Shares Out | 177.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,966 |
| Open | 3.120 |
| Previous Close | 3.110 |
| Day's Range | 3.090 - 3.138 |
| 52-Week Range | 2.308 - 4.800 |
| Beta | 1.24 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+126.54%) |
| Earnings Date | May 6, 2026 |
About EVO
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and c... [Read more]
Financial Performance
In 2025, Evotec SE's revenue was 788.37 million, a decrease of -1.08% compared to the previous year's 796.97 million. Losses were -103.52 million, -47.21% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to one analyst, the rating for EVO stock is "Strong Buy" and the 12-month stock price target is $7.0.
News
Evotec (EVO) Secures Funds from Gates Foundation for TB Drug Development
Evotec (EVO) Secures Funds from Gates Foundation for TB Drug Development
Evotec SE: Evotec Receives Grants to Advance Tuberculosis Treatment
Grants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testingNew funding from the Gates Foundation extends Evote...
Evotec Receives Grants to Advance Tuberculosis Treatment
Grants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testing New funding from the Gates Foundation extends Evotec'...
Evotec SE: Evotec Announces New Nomination to Board of Directors
Nomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilitiesConclusion of cooperation agreement with MAK Capital following ...
Evotec Announces New Nomination to Board of Directors
Nomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilities Conclusion of cooperation agreement with MAK Capital following co...
Evotec SE to Announce First Quarter 2026 Results on May 6, 2026
HAMBURG, DE / ACCESS Newswire / April 29, 2026 / Evotec SE (NASDAQ:EVO; Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first quarter 2...
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Friday. Shares of Boyd Gaming Corp (NYSE: BYD) fell sharply in pre-market trading after the company repor...
Evotec CFO Paul Hitchin Resigns; Names Claire Hinshelwood Replacement
(RTTNews) - Evotec SE (EVO, EVTG.DE, EVTCY.PK), a life science company, announced Friday that its CFO Paul Hitchin will leave the company on April 30, "citing personal reasons unrelated to Evotec."
Evotec Announces Chief Financial Officer Transition
Paul Hitchin to step down as of April 30, 2026 Claire Hinshelwood appointed to CFO role as of May 1, 2026 HAMBURG, DE / ACCESS Newswire / April 24, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standa...
Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer
Will play key role in strengthening cross-functional execution in support of global platform, scientific capabilities and partner delivery as well as the execution of the Horizon initiative Brings mor...
Evotec (EVO) Q3 2025 Earnings Call Transcript
Evotec (EVO) Q3 2025 Earnings Call Transcript
Evotec SE (EVOTF) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue Challenges
Evotec SE (EVOTF) Q4 2025 Earnings Call Highlights: Strategic Gains Amid Revenue Challenges
Q4 2025 Evotec SE Earnings Call Transcript
Q4 2025 Evotec SE Earnings Call Transcript
Earnings Scheduled For April 8, 2026
Companies Reporting Before The Bell • Beasley Broadcast Group (NASDAQ: BBGI) is projected to report earnings for its fourth quarter. • RPM International (NYSE: RPM) is projected to report quarterly ...
MAK Capital Urges Evotec To Pursue U.S. Listing For Just Biologics
WASHINGTON (dpa-AFX) - MAK Capital is urging Evotec SE to take its U.S. subsidiary, Just Biologics, public and to accelerate its cost-cutting measures. They believe more decisive steps are necessa...
What To Expect From Evotec SE (XTER:EVT) Q4 2025 Earnings
What To Expect From Evotec SE (XTER:EVT) Q4 2025 Earnings
Evotec vows to further engage with investor MAK, who demanded change
Evotec said on Tuesday it would continue a dialogue with investor MAK Capital, which has published a list of changes it wants the German biotech firm to make.
Evotec SE: Evotec Nominates Dieter Weinand as Supervisory Board Chairman
Strengthens Supervisory Board leadership to support Evotec's transformation, with a focus on commercial execution, strategic partnerships and profitabilityIndustry veteran brings more than 30 years...
Evotec Nominates Dieter Weinand as Supervisory Board Chairman
Strengthens Supervisory Board leadership to support Evotec's transformation, with a focus on commercial execution, strategic partnerships and profitability Industry veteran brings more than 30 years o...
EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Evotec SE Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 02.04.202...
Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026
HAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) will hold a webcast and conference call to announce its financial results for the fourth quarter an...
Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer
HAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer.
Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
The program leverages Just - Evotec Biologics' advanced biomanufacturing platform to deliver high-quality, scalable, cost-efficient production through significantly higher yields Manufacturing process...
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer Transformative moment i...
Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Evotec SE (NASDAQ: EVO). The investigation focuses on Evotec executive of...